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Background: The ubiquity of protein-protein interactions in biological signaling offers ample opportunities for
therapeutic intervention. We previously identified a peptide, designated CBD3, that suppressed inflammatory and
neuropathic behavioral hypersensitivity in rodents by inhibiting the ability of collapsin response mediator protein 2
(CRMP-2) to bind to N-type voltage-activated calcium channels (CaV2.2) [Brittain et al. Nature Medicine
17:822–829 (2011)].
Results and discussion: Here, we utilized SPOTScan analysis to identify an optimized variation of the CBD3
peptide (CBD3A6K) that bound with greater affinity to Ca2+ channels. Molecular dynamics simulations
demonstrated that the CBD3A6K peptide was more stable and less prone to the unfolding observed with the
parent CBD3 peptide. This mutant peptide, conjugated to the cell penetrating motif of the HIV transduction
domain protein TAT, exhibited greater anti-nociception in a rodent model of AIDS therapy-induced peripheral
neuropathy when compared to the parent TAT-CBD3 peptide. Remarkably, intraperitoneal administration of
TAT-CBD3A6K produced none of the minor side effects (i.e. tail kinking, body contortion) observed with the parent
peptide. Interestingly, excitability of dissociated small diameter sensory neurons isolated from rats was also reduced
by TAT-CBD3A6K peptide suggesting that suppression of excitability may be due to inhibition of T- and R-type
Ca2+ channels. TAT-CBD3A6K had no effect on depolarization-evoked calcitonin gene related peptide (CGRP)
release compared to vehicle control.
Conclusions: Collectively, these results establish TAT-CBD3A6K as a peptide therapeutic with greater efficacy in an
AIDS therapy-induced model of peripheral neuropathy than its parent peptide, TAT-CBD3. Structural modifications
of the CBD3 scaffold peptide may result in peptides with selectivity against a particular subset of voltage-gated
calcium channels resulting in a multipharmacology of action on the target.
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Neuropathic pain most commonly arises from injury to
the nervous system but can also be attributed to disease
and/or administration of toxic drugs (i.e. AIDS therapy).
Despite a range of available analgesics, neuropathic pain
remains a large unmet medical need. The lack of anal-
gesic efficacy may be due to the fact that specific ion
channels contribute to the mechanisms underlying the
numerous neuropathic pain syndromes. Accumulating
evidence identifies adaptive changes in ion channels as a
mitigating factor in the molecular etiology of numerous
neuropathic pain syndromes.
A variety of voltage-dependent and independent ion
channels in addition to nonselective cation channels can
influence neurons associated with the nociceptive path-
way. Voltage-activated ionic currents are critical to the
excitability of nociceptive neurons present in the dorsal
root ganglia. Notably, sodium and calcium currents
serve to respectively set the threshold and upstroke of
action potential (AP) firing as well as facilitating fre-
quency and sustainability of AP firing [1]. While it is
generally accepted that an increase in Na+ channel dens-
ity following nerve injury can influence the hyperexcit-
ability of sensory neurons, Ca2+ channel subtypes
modulate nociceptive signal transduction by influencing
synaptic transmission and can enhance cellular excitabil-
ity by producing subthreshold membrane oscillations
and spike firing within the sensory neurons [2]. Voltage-
activated Ca2+ channels can be classified as sustained
high voltage-activated calcium channels (HVACC) and
transient low voltage-activated calcium channels
(LVACC), also known as T-type (CaV3.1–3). HVACC in-
clude N-type (blocked by ω-conotoxin GVIA; CaV2.2),
P/Q-type (blocked by ω-agatoxin IVA; CaV2.1) and R-
type (resistant to other toxins; CaV2.3). Investigation
into the manner in which the LVACC subtypes contrib-
ute to depolarizing potential waves and to burst firing
following membrane hyperpolarization has yielded evi-
dence to suggest that inhibition of T-type Ca2+ currents
using the anti-hypertensive drug, mibefradil, can reverse
stimulus-dependent neuropathic pain behavior [3]. As
mibefradil does not cross the blood–brain barrier, this
antihyperalgesic effect is thought to be largely localized
to the primary afferent neuron [4-6]. Taken together,
these studies position T-type calcium channels as prom-
ising therapeutic targets.
In addition to T-type Ca2+channels, HVACC R-type
Ca2+channels have recently been shown to play a role in
nociception and neuropathic pain [7,8]. R-type calcium
currents are present in rat DRG neurons and have been
shown to contribute to neuronal excitability [9-11] as R-
type channel knockout mice exhibit reduced responses to
inflammatory pain stimuli [7]. In addition, an antagonist
of R-type Ca2+current, has been shown to contribute toneuronal responses in a spinal nerve ligation (SNL)
model of chronic neuropathic pain [8]. While a complete
understanding of the role of R-type calcium channels in
chronic pain states is in its infancy, these studies suggest
the R-type Ca2+ channel may be a potential target for
analgesics to reduce nociceptive signaling.
Many pharmacotherapeutic agents targeting T- and R-
type calcium channels are designed to impact state-
dependenttransitions.Here,weuseanalternativeapproach:
to target modulators of channel trafficking. A recently
discovered interaction between the N-type calcium
channel, CaV2.2 and collapsin response mediator protein
2 (CRMP-2) positively regulated channel functions by
increasing CaV2.2’s cell surface trafficking [12-14]. This
CaV2.2 trafficking at the membrane can be effectively
disrupted by a short peptide (CBD3) corresponding to a
15 amino acid region of CRMP-2 [12]. CBD3 peptide
reduced CaV2.2-mediated currents important for neuro-
peptide release from sensory neurons and excitatory syn-
aptic transmission in dorsal horn neurons of the spinal
cord. Additionally, CBD3 administration in vivo reduced
hypersensitive behavior in a number of pain models, in-
cluding a model of neuropathic pain induced by anti-
retroviral drug treatment. Here, we tried to improve the
parent CBD3 peptide’s efficacy on attenuating neuro-
pathic pain in vivo and identify other possible mechan-
isms underlying its analgesic effects. We were successful
with a derivative peptide, TAT-CBD3A6K, whose admin-
istration exhibited greater anti-nociceptive effects in a
model of AIDS-induced peripheral neuropathy com-
pared to the parent CBD3 peptide. Interestingly, the ex-
citability of dissociated small diameter sensory neurons
isolated from antiretroviral therapy-treated rats was
reduced by TAT-CBD3A6K likely via an effect on T- and
R-type calcium channels. In summary, TAT-CBD3A6K
alleviates neuropathic hypersensitivity by preventing
CRMP-2-mediated enhancement of T- and R-type cal-
cium channel function, an approach that may prove use-
ful in managing chronic neuropathic pain.
Results
CBD3 peptide and identification of mutant CBD3 peptides
with altered binding to Ca2+channels
We had previously mapped several CaV binding domains
(CBDs) on CRMP-2 that conferred binding to CaV2.2
[12]. Refinement of the mapping resulted in identifica-
tion of a 15 amino acid peptide, designated CBD3, which
was sufficient to confer the interaction [15]. Fusing
CBD3 to the transduction domain of the HIV TAT pro-
tein resulted in a cell permeable biologic, which by pre-
venting CRMP-2-mediated enhancement of CaV2.2
function, alleviated inflammatory and neuropathic hyper-
sensitivity [15]. Only 6 of 15 amino acids of CBD3 are
present in the CRMP-2 structure (Figure 1A, B) and
Piekarz et al. Molecular Pain 2012, 8:54 Page 4 of 19
http://www.molecularpain.com/content/8/1/54structure-based homology models derived using a
multiple-template threading statistical method (RaptorX,
[16]) reveal that the carboxyl 9 amino acids are largely
unstructured (data not shown). The lack of structural ri-
gidity and accessibility of CBD3 may be inherently bene-
ficial in blocking protein-protein interactions and offers
possibilities for peptide optimization. We hypothesized
that single amino-acid mutation scans of the CBD3 se-
quence may yield superior peptide derivatives not only
with respect to CaV2.2 binding but perhaps also with re-
spect to blocking Ca2+ channel function, transmitter re-
lease, and ultimately hypersensitivity. To this end, we
performed a limited mutational scan of the CBD3 pep-
tide and discovered three peptides with point mutations
at positions 6 (A6K), 9 (R9L) and 14 (G14F) with greater
binding to Ca2+ channels than the parent CBD3 peptide
(Figure 1C). We have already demonstrated that dural
application of TAT-CBD3A6K is better at inhibiting cap-
saicin (Cap)-evoked meningeal vasodilation in a rodent
model of headache pain than the parental CBD3 peptide
[17]. This data suggests that peptide optimization strat-
egies do indeed result in sister peptides with enhanced
actions, potentially lowering the potential for off-target
effects.Figure 1 Scanning mutagenesis of CBD3 identifies better Ca2+channe
top of surface representations of the three-dimensional structure of the CR
the 6 amino acids of the CBD3 peptide are illustrated in the boxed region.
acids (yellow; denoted in single letter code) of CBD3. (C) Matrix representa
mutated in silico to the indicated amino acids (italicized boldface font). The
mutations at position 6 (A6K), 9 (R9L) and 14 (G14F) displayed the highestMolecular dynamics (MD) simulations of wild type and
mutant CBD3 peptides
As a further test of our peptide stability hypothesis, MD
simulations were carried out to explore atomistic flexibil-
ity of wild type and A6K mutant peptides in solution. A
three-dimensional structure for wild type and A6K mu-
tant peptide was constructed. The structure was
immersed in a box of explicit-solvent molecules and sub-
jected to 10 separate trajectories consisting of 10 ns of
simulation for a total of 100 ns of dynamics per peptide.
The evolution of the structure of each peptide over the
course of a trajectory is quantified with the root-mean-
squared deviation (RMSD), a measure of the deviation of
the peptide from its original structure. Following 2 ns of
equilibration, the RMSDs for the wild type and
CBD3A6K mutant trajectories are shown in Figure 2A
and B. For the wild type peptide, the structures of 8 of
the 10 trajectories sampled during the course of the
simulation fluctuate between 1 and 3 Å. The remaining
two wild type trajectories show significant deviation from
the initial structure with RMSDs greater than 4 Å, and in
one case greater than 5 Å (green curve in Figure 2A).
Visualization of this trajectory reveals that at 2 ns, the
structure gradually adopts a more compact structurel binding derivative peptides. (A) Superimposed ribbon overlaid on
MP-2 monomer (RCSB databank PDB code: 2GSE) [79]. The location of
(B) Ribbon representation of the helix harboring the first 6 amino
tion of normalized binding of CaV2.2 to CRMP-2 peptides singly
matrix was generated by Matrix2png [79]. Three peptides with
binding to CaV2.2.
Figure 2 Molecular dynamics (MD) simulations of wild type and mutant CBD3 peptides. Conformational change experienced by (A) wild
type CBD3 and (C) CBD3A6K mutant peptides over the course of multiple 10 ns MD simulations. Snapshots at 0, 5 and 10 ns of stereo pairs for
(B) wild type and (D) mutant peptides are shown in capped-sticks representation, color-coded by atom type (C, N, and O in green, blue and red).
The overall structure of the peptide is depicted in ribbon representation. RMSD, root mean square deviation (in angstroms).
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acid is located near the N-terminus of the peptide (See
animation in Additional File 1). The CBD3A6K mutant
peptide trajectories show that the RMSD for this peptide
also fluctuates between 1 and 4 Å (See animation in
Additional File 1). While none of the A6K mutant
peptide trajectories showed dramatic conformational
changes that were seen in some of the wild type trajec-
tories, mutant structures showed a higher degree of con-
formational change than wild type. For example, most of
the mutant trajectories revealed RMSDs greater than 3 Å
starting at 5 ns for the remainder of the simulation. For
wild type, only one trajectory showed similar RMSDs.
Snapshots for mutant peptide collected at 5 and 10 ns
are shown in Figure 2D. Like the wild type peptide, the
C-terminus residues are less stable than N-terminus resi-
dues, which consistently maintain an α-helical structure
throughout the trajectory. Increased conformational
change of the mutant peptide may result in greater effi-
cacy for this peptide. Greater conformational change
suggests that the peptide may sample alternative con-
formational states that are more prone to bind to the cal-
cium channel and inhibit its interaction with CRMP-2.
The wild type peptide appears more prone to undergo
dramatic structural changes that are not seen in the A6Kmutant simulations. The lack of such disruptions to the
mutant peptide could be another reason that these pep-
tides show greater efficacy.
TAT-CBD3A6K attenuates AIDS therapy-induced painful
peripheral neuropathy
Having identified potentially superior peptides with re-
spect to channel binding, we next tested the efficacy of the
best (i.e. A6K) peptide on chronic nociceptive behavior in
an animal model of AIDS therapy-induced painful neur-
opathy [18]. Nucleoside reverse transcriptase inhibitors
(NRTIs), part of the highly active antiretroviral treatment
(HAART) for AIDS includes drugs such as zidovudine
(AZT), zalcitabine (ddC), didanosine (ddI) and stavudine
(d4T) that produce side-effects including painful neuropa-
thies. Many of these drugs, including d4T, produce long
lasting pain hypersensitivity in humans [19,20] and
rodents, but no changes in motor coordination [18]. To
study changes in tactile pain sensitivity following a single
injection of d4T, we investigated alterations in the thresh-
old force of indentation (produced by von Frey filaments)
necessary for eliciting a flexion hindpaw withdrawal reflex.
A single administration of d4T (50 mg/kg) produced a sig-
nificant bilateral decrease in paw withdrawal threshold to
von Frey hair stimulation from post-injection day (PID) 3
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dent’s t-test) (Figure 3).
To determine if TAT-CBD3 and TAT-CBD3A6K could
attenuate tactile hyperalgesia elicited by d4T, we adminis-
tered a single systemic dose of TAT-conjugated versions
of CBD3 (30 mg/kg and 10 mg/kg) or CBD3A6K (10 mg/
kg) i.p. to d4T-treated rats. Tactile hyperalgesia was
assessed 1 and 4 hours following injection of peptides.
Systemic injection of either TAT-CBD3 (10 mg/kg) or
TAT-CBD3A6K in naïve rats did not alter baseline paw
withdraw threshold (PWT) at 1 or 4 hours post injection
(pre-d4T mean=78.0± 10.8 mN for control vs. 78.6 ± 1.0
mN 1 hour post TAT-CBD3 and 75.3± 0.9 mN 4 hours
post TAT-CBD3; p> 0.05, Figure 3) and pre-d4T mean=
74.3± 1.0 mN for control vs. 75.7 ± 1.2 mN 1 hour post
TAT-CBD3A6K and 74.7± 1.2 mN 4 hours post TAT-
CBD3A6K; p> 0.05, Figure 3). However, 1 h after 30 mg/
kg of TAT-CBD3 was administered to d4T-treated rats;
PWT was partially reversed to control levels (68.8 ± 1.7
mN; p< 0.05, Figure 3). The duration of TAT-CBD3’s ef-
fect was short lived as PWTs returned to pre-peptide
levels by 4 hours (42.5 ± 4.9 mN). A lower dose of TAT-
CBD3 (10 mg/kg) also significantly attenuated d4T-
elicited hyperalgesia albeit to a lesser degree than the
30 mg/kg dose. One h after 10 mg/kg of TAT-CBD3 was
administered to d4T rats, PWT was higher by ~64% com-
pared to pre-peptide levels (p< 0.05, Figure 3). Similar to
the 30 mg/kg dose, PWTs returned to predosing levels 4 h
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Figure 3 Effect of TAT-CBD3 and TAT-CBD3A6K peptides on d4T-indu
measured in d4T-treated rodents exhibiting mechanical hypersensitivity be
significantly reduced in d4T-treated rodents (white bars). A single intraperit
not 10 mg/kg body weight, attenuates d4T-induced mechanical hypersens
post hoc test; n = 6). Administration of a 10 mg/kg i.p. dose of TAT-CBD3A6
at least 4 hours (#, p< 0.01, RMANOVA with Newman-Keul post hoc test; n
reverse peptides did not alter d4T-mechanical hypersensitivity (n = 3).Remarkably, a 10 mg/kg dose of the derivative peptide
TAT-CBD3A6K had greater efficacy in attenuating d4T-
elicited hyperalgesia than that of the parent TAT-CBD3 at
a dose of 30 mg/kg. 1 h after 10 mg/kg of TAT-CBD3A6K
was administered to d4T rats, PWT was fully reversed to
control levels (82.2 ± 0.8 mN; p> 0.05; repeated measures
analyses of variance (RMANOVA) followed by post hoc
pairwise comparisons (Student-Newman-Keuls Method)
and significantly higher pre-peptide levels (43.3 ± 1.10
mN; p< 0.05 Figure 3). Additionally, PWTs were signifi-
cantly higher than pre-peptide dosing levels by 4 hours
(72.9 ± 1.3 mN, p< 0.05, Figure 3). All effects of TAT-
CBD3 peptides returned to pre-peptide levels 24 h post
injection (data not shown). A reverse of TAT-CBD3 pep-
tide (TAT-CBD3 reverse) had no effects on PWT at 1 and
4 hours post injection (p> 0.05, Figure 3). These results
suggest that the TAT-CBD3 and TAT-CBD3A6K peptides
are effective in blocking AIDS therapy-induced painful
peripheral neuropathy.
TAT-CBD3 peptides reduce the excitability of nociceptive
DRG neurons
Peripheral neuropathy is often a result of hyperexcitability
of peripheral sensory neurons. Compounds that have been
shown to inhibit sensory neuron excitability also attenuate
neuropathic pain [21]. Additionally, the attenuation of
neuropathic pain with peripherally acting compounds
such as mibefradil suggests that its analgesic effects are





   
   





















































ced mechanical hypersensitivity. Paw-withdrawal thresholds were
fore and after TAT-CBD3 mutant peptide. Nociceptive thresholds were
oneal (i.p.) administration of TAT-CBD3 at 30 mg/kg body weight, but
itivity for at least 1 hour (#, p< 0.01, RMANOVA with Newman-Keul
K significantly attenuated d4T-induced peripheral hypersensitivity for
= 6). Administration of a 10 mg/kg i.p. dose of TAT-CBD3 or TAT-CBD3
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neuropathic pain through a decrease in transmitter release
and excitatory synaptic transmission in the spinal cord via
a reduction in N-type calcium current [15], it was plaus-
ible that this peptide also acts on calcium channels that
control neuronal excitability in neurons, namely the T-
and R-type calcium channels [22,23]. However, this possi-
bility was not previously explored. Thus, to examine the
possibility that these peptides affect the neuronal excitabil-
ity of dissociated DRG neurons, we tested small-to-
medium (>30 μm – >40 μm) sensory neuron excitability
before and after addition of 10 μM TAT-CBD3 and TAT-
CBD3A6K. We used current clamp recordings to test for
possible direct effects of TAT-CBD3 and TAT-CBD3A6K
on the overall excitability of DRG neurons from d4T-
treated rats. The excitability was measured by injecting
current pulses (nA) into the soma of small diameter DRG
neurons every 30 seconds in order to elicit 4–6 action
potentials (average current injection of 0.6 ± 0.1 nA
(n= 16)) under control conditions prior to the addition of
peptides into the recording bath. Representative record-
ings (Figure 4A, B, D, E) and grouped data (Figure 4C, F)
show that the excitability of small diameter DRG neurons
was decreased by both TAT-CBD3 and TAT-CBD3A6K.
Five minutes following perfusion of CBD3, there was on
average a ~74.1% reduction in the number of action
potentials elicited by a current pulse compared to controlControl TA
Control TAT
-48 mV -48 mV










Figure 4 TAT-CBD3 and TAT-CBD3A6K peptides reduce the excitabilit
recordings were performed on small-to-medium (>30 μm– >40 μm) diam
action potentials (APs) was elicited by a 1 second depolarizing current inje
seconds (A, D). Representative recordings demonstrating that application o
potentials (B, E). Group data showing that TAT-CBD3 (C) and TAT-CBD3A6K
(*, p <0.05 versus control, Student’s t-test; n = 8 each).(1.1 ± 0.3 APs with TAT-CBD3 versus 4.4 ± 0.7 APs
without TAT-CBD3 (n= 8) (Figure 4A, B, C; *, p <0.05,
Student’s t-test). Additionally, five minutes following per-
fusion of TAT-CBD3A6K, there was on average a ~68.8%
reduction in the number of action potentials elicited
by a current pulse compared to control (1.8 ± 0.3 APs
with TAT-CBD3A6K versus 5.8 ± 0.4 APs without TAT-
CBD3A6K (n= 8) (Figure 4D, E, F; *, p <0.05, Student’s t-
test). Both TAT-CBD3 and TAT-CBD3A6K peptides failed
to alter the neuronal resting membrane potential (control
−50.9 ± 1.4 mV (n=8) vs. –50.4 ± 1.7 mV (n= 8) following
CBD3 application; and control −54.1± 2.7 mV (n=7) vs.
–55.3± 3.1 mV (n=7) for A6K; p> 0.05 for both TAT-
CBD3 and TAT-CBD3A6K). These results suggest that
DRG excitability can be affected by TAT-CBD3 peptides.
Effect of TAT-CBD3 and TAT-CBD3A6K peptides on T- and
R-type calcium currents in DRG neurons
We previously demonstrated that TAT-CBD3 reduces
HVACC, most notably N-type calcium currents in DRG
neurons [15]. Whether T- and R-type calcium currents
were affected by the CBD3 peptide was not explored.
Based on the observations that: (i) T-type channels are
available for opening only from very negative membrane
potentials and are thus ideally positioned for regulating
neuronal excitability [2,9,24,25], (ii) R-type channels




















































y of nociceptive dorsal root ganglia (DRG) neurons. Current clamp
eter lumbar 4–5 DRG neurons from d4T-treated rats. Firing of 4–6
ction (ranging from 0.1 to 0.4 nA depending on the cell) every 30
f 10 μM CBD3 and CBD3A6K reduces the number of elicited action
(E) caused a significant reduction in DRG action potential firing
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idal hippocampal neurons [23], and (iii) our findings that
DRG excitability can be affected by CBD3 peptides, we
asked if CBD3 peptides affect T- and R-type calcium
currents in DRGs. For these studies, we focused primar-
ily on the TAT-CBD3A6K peptide as MD simulations
showed a higher propensity of conformational change
which may be responsible for the greater efficacy
observed for the peptide at attenuating neuropathic pain,
combined with its lack of effects on whole-body contor-
tion or tail kinking observed with the parent TAT-CBD3
peptide (n = 6 each), and equal, if not better efficacy than
the parent TAT-CBD3 in suppressing DRG excitability.
Whole-cell voltage clamp recordings were made from
acutely dissociated small-to-medium (>30 μm - >40 μm)
diameter sized rat lumbar 4–5 DRG neurons. In order to
isolate calcium currents in DRG neurons recordings
were acquired with an extracellular solution containing
500 nM TTX and 110 mM N-methyl-D-glucamine to
suppress inward sodium currents. Additionally, 5 μM Ni-
fedipine, 500 nM ω-Conotoxin GVIA, and 200 nM ω-
Agatoxin IVA were added to the extracellular recording
solution to block L-, N- and P/Q-type currents, respect-
ively. Under such recording conditions recorded Ba2+
currents can only be carried by the T- or R-type calcium
currents. Whole-cell Ba2+ currents were elicited from a
holding potential of −90 mV to depolarizing test poten-
tials (ranging from–60 mV to +50 mV in 5 mV incre-
ments) for 200 ms. Figure 5A shows representative
voltage-dependent inward currents (IBa) from DRG neu-
rons with fast kinetic properties (i.e. T-type, top traces)
similar to those reported previously [2] as well as those
with kinetically slow (i.e. R-type, bottom traces) proper-
ties. A normalized conductance versus condition voltage
plot (Figure 5B) shows clear separation between LVACC
(T-type) from HVACC (R-type) currents: at −10 mV, T-
type calcium currents contribute to >80% of the con-
ductance with R-type contributing <3% (Figure 5B,
dotted line). Using a ramp protocol (depolarizations
from −60 mV to +20 mV for 2 sec) which allows for
rapid screening of the presence of LVACC and HVACC,
we observed both T- and R-type currents in the same
DRG (Figure 5C) neuron which were inhibited by ~35%
and ~55%, respectively, within 2 minutes of application
of TAT-CBD3A6K (Figure 5C).
In order to better characterize the extent of the
peptide-mediated inhibition of calcium currents, we
performed time course experiments with TAT-CBD3A6K
. Figure 6A shows a representative family of T- and R-
type calcium currents in a DRG before (leftmost traces),
at 2 min following bath perfusion of 10 μM TAT-
CBD3A6K (middle traces), and at 5 min after the peptide
was added (rightmost traces). Representative currents,
elicited at −10 mV — a voltage at which R-type currentsaccount for <3% of the current — show a progressive de-
velopment of peptide-mediated inhibition of T-type
current (Figure 6B). Five minutes following perfusion of
TAT-CBD3A6K, there was a ~43.6% reduction in peak
T-type currents compared to control (normalized current
density: 0.62 ± 0.08 (n = 3) with TAT-CBD3A6K versus
1.1 ± 0.1 (n = 3) without TAT-CBD3A6K (Figure 6B; *,
p <0.05, Student’s t-test). At the same time following
perfusion of CBD3A6K, there was a ~52.0% reduction in
peak R-type currents compared to control (normalized
current density: 0.76 ± 0.05 (n = 3–6) withTAT-CBD3A6K
versus 1.6 ± 0.2 (n = 3–6) without TAT-CBD3A6K
(Figure 6C; *, p <0.05, Student’s t-test). Significant run
up of LVACC and HVACC was observed in our record-
ings, consistent with previous reports [26-28]. Neverthe-
less, the inhibition occurred faster for the R-type
currents compared with the T-type currents but plat-
eaued at around 4 min following addition of peptide.
Since development of current inhibition develops
slowly and stable recordings (lasting ≥10 min) with pep-
tide were not readily obtainable, we chose to further
examine peptide-mediated inhibition of T- and R-type
currents in bath-applied population studies. These mea-
surements were conducted at least 10 min following
addition of peptides, a time point well beyond that at
which all run up phenomena has normalized. As select-
ive blockers or R- and T-type currents were not used in
these studies, cells with only R-type or only T-type cur-
rents were used in the analyses with T-type being mea-
sured at −10 mV and R-type at +20 mV; at the latter
voltage almost all T-type current is inactivated [29]. T-
type calcium current density was decreased by ~75%
and ~48% by TAT-CBD3 and TAT-CBD3A6K, respect-
ively (Vt =−10 mV, p <0.05, one-way analysis of variance
versus respective controls; see Figure 7E). Additionally,
the R-type calcium current density was decreased by
~35% (Vt = +20 mV, p <0.05, one-way analysis of
variance versus control) in TAT-CBD3A6K-treated neu-
rons (see Figure 7E). In contrast, TAT-CBD3 did not
affect R-type currents: 54.9 ± 6.5 (n = 9) in control DRGs
versus 70.3 ± 9.9 (n = 13) pA pF-1 in TAT-CBD3-treated
neurons. In summary, TAT-CBD3A6K peptide blocks
both T- and R-type calcium currents in sensory neurons.
Effect of TAT-CBD3A6K on evoked transmitter release
from isolated sensory neurons
We previously demonstrated that TAT-CBD3 reduces
release of the neuropeptide transmitter calcitonin gene
related peptide (CGRP) from sensory neurons [13]. Here
we asked if TAT-CBD3A6K could have a similar effect.
Two stimulation paradigms were used to evoke release
from all (with 50 mM potassium chloride; KCl) or pre-
sumptive nociceptive (with 30 nM Capsaicin; Cap)
DRGs. The KCl- or Cap-stimulated release of CGRP was
Figure 5 Pharmacological and biophysical dissection of TAT-CBD3A6K-mediated block of T-and R-type calcium currents in DRG
neurons. (A) Representative T- (top) and R-type (bottom) current traces obtained from two separate DRG neurons evoked by 200 ms steps in
5 mV increments from −60 mV to +50 mV, from a holding potential of −90 mV. The extracellular bath solution contained 5 mM Nifedipine (Nif),
200 nM ω-Agatoxin IVA (Aga) and 500 nM ω-Conotoxin GVIA (CTX) to block L-, P/Q-, and N-type calcium currents, respectively. (B) Summary of
the normalized conductance (G) versus voltage relations for DRG neurons with T- (filled squares) or R- (open squares) type calcium currents.
The dotted line at −10 mV highlights the clear discrimination in conductances between T- and R-type currents. (C) Representative currents,
evoked by a ramp depolarizations from −60 mV to +20 mV for 2 s, illustrating the presence of both T- and R-type currents in the same DRG
neuron before (left trace) and 2 min after application 10 μM TAT-CBD3A6K (right trace).
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TAT-CBD3A6K (10 μM) included in the 10 minutes
prior to and throughout the high K+/Cap exposures
(total peptide exposure of 30 min). The levels of basal or
resting release of immunoreactive CGRP (iCGRP) were
not significantly different between any of the groups
tested: (for high K+ experiments: 1.67 ± 0.14% total pep-
tide content/10 min (n = 12 wells) in untreated control
neurons compared to 1.32 ± 0.10% total peptide content/
10 min (n = 12 wells) in TAT-CBD3A6K peptide-treated
neurons; for Cap-stimulated experiments: 1.73 ± 0.25%
total peptide content/10 min (n = 9 wells) in untreated
control neurons compared to 1.30 ± 0.17% total peptidecontent/10 min (n = 9 wells) in TAT-CBD3A6K-treated
neurons). A 10 min stimulation with 50 mMKCl or 30
nM Cap evoked a robust increase (~10-fold over basal)
in iCGRP release in untreated and TAT-CBD3A6K-
treated neurons (Figure 7A, C, p> 0.05, ANOVA). The
evoked release, obtained by subtracting iCGRP release
during the two initial basal fractions from that during
the potassium or capsaicin-stimulated fractions and
expressing it as percent of total iCGRP content in each
group, was not different between untreated and TAT-
CBD3A6K-treated neurons in experiments with K+
evoked release (Figure 7A, p> 0.05). The total cellular
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Time (min) post 
peptide addition
Figure 6 Characterization of TAT-CBD3A6K-mediated inhibition of T- and R-type calcium currents. (A) Representative family of traces from
a DRG neuron with both T- and R-type calcium currents before (left), 2 min (middle) and 5 min (right) after addition of 10 μM TAT-CBD3A6K.
Currents were elicited in response to the voltage protocol described in the legend to Figure 5A. To isolate T- and R-type calcium currents, the
extracellular bath solution contained 5 mM Nifedipine (Nif), 200 nM ω-Agatoxin IVA (Aga) and 500 nM ω-Conotoxin GVIA (CTX) to block L-, P/Q-,
and N-type calcium currents, respectively. (B, C) Time course of TAT-CBD3A6K mediated inhibition (“run-down”) of T-type (B) and R-type (C)
calcium currents. Time course of inhibition is shown as averaged normalized current density (pA pF-1) before peptide addition and at intervals of
30 s for 5 min. Averaged values are shown with standard error for 4–6 control cells and 4 cells following addition of 10 μM TAT-CBD3A6K. The
asterisk denotes statistical significance (p< 0.05; Student’s t-test) compared to the corresponding control time point. Some error bars are smaller
than the symbols. Data represent mean± SEM from n= 3–6 cells at each time point except for n = 2 the 4 min time point for T-type currents in
the presence of peptide.
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p> 0.05). In contrast, in experiments with Cap, the evoked
release was ~32% less in neurons treated with TAT-
CBD3A6K compared to control neurons (Figure 7C,
p< 0.05; ANOVA with Dunnett’s post-hoc test). The
decrease in Cap-stimulated iCGRP release observed in
TAT-CBD3A6K-treated neurons was not caused by an
increase in the total cellular content of iCGRP as there was
no significant difference in neuropeptide content between
the two conditions (Figure 7D). These results show a
stimulus-dependent effect of TAT-CBD3A6K on iCGRP
release from sensory neurons.
Discussion
Neuropathic pain can result from primary dysfunction
of peripheral nociceptive sensory neurons. This pain
outlasts the early stage of injury and frequently leads to
debilitating disorders that are not responsive to conven-
tional analgesic drug therapies. It has been suggested by
a number of groups that regulation of voltage-activated
calcium channels may contribute to hyperexcitability of
the primary afferent neuron associated with chronic painstates [21,30-33]. An emerging approach to treating
neuropathic pain is to target ion channels on sensory
neurons that play a role in neuronal excitability and
neurotransmitter release. Two candidate ion channels
have been shown to control neuronal excitability and
neurotransmitter release in peripheral sensory neurons:
the T- and N-type calcium channels, respectively. Add-
itionally, R-type calcium channels can control neuronal
burst firing. As was previously reported, a peptide of
CRMP-2 fused to the HIV transactivator of transcription
(TAT) protein (TAT-CBD3) decreased neuropeptide re-
lease from sensory neurons and excitatory synaptic
transmission in dorsal horn neurons via inhibition of
CaV2.2 [15]. This peptide also significantly reduced noci-
fensive behavior induced by formalin injection or cor-
neal capsaicin application and reversed neuropathic pain
produced by an antiretroviral drug [15]. Here we report
that a TAT-conjugated peptide derivative of CBD3, TAT-
CBD3A6K, may decrease neuronal excitability of DRG
sensory neurons via inhibition of T- and R-type calcium
currents and attenuates neuropathic pain in the Stavudine
















































































































+ 50 mM KCl
+ 30 nM Cap
Figure 7 Effects of TAT-CBD3A6K on evoked transmitter release
and TAT-CBD3 and TAT-CBD3A6K on T- and R-type calcium
currents. (A, C) Adult rat DRG neurons were maintained in culture
for 12–14 days prior to the release experiments. Bar graph of
immunoreactive calcitonin gene-related peptide (iCGRP) release
expressed as mean percent total iCGRP content of cells in each
well ± s.e.m. (n = 9-12 wells/condition as indicated). Neuropeptide
release was measured from cells treated with normal HEPES buffer
containing 3.5 mM KCl, HEPES buffer containing 10 μM TAT-
CBD3A6K, HEPES buffer containing 50 mM KCl or 30 nM Capsaicin
(Cap), followed by a final HEPES buffer containing 3.5 mMKCl again.
DRGs were exposed to vehicle or TAT-CBD3A6K peptide, at 10 μM,
included in the 10 minutes prior to and throughout the high
(50 mM) potassium (A) or 30 nM capsaicin (C) challenges. The
resulting total TAT peptide exposure time was for 30 min. There was
no significant difference in the high potassium-evoked iCGRP release
(A) between TAT-CBD3A6K and the control (no treatment) using an
ANOVA with Dunnett’s post-hoc test (p> 0.05). The Cap-evoked
iCGRP release significantly less in neurons treated with TAT-CBD3A6K
compared to control neurons (C, *, p< 0.05; ANOVA with Dunnett’s
post-hoc test). The evoked release was obtained by subtracting
iCGRP release during the two initial basal fractions from that during
the potassium or capsaicin-stimulated fractions and expressing it as
percent of total iCGRP content in each group. In all cases, release
stimulated by high potassium or capsaicin was significantly higher
than basal release. (B, D) The total content of iCGRP measured at
the end of the release experiments for either high potassium (A) or
30 nM capsaicin (C) challenges. There were no significant differences
in iCGRP content between the conditions tested (p> 0.05). (E) Bar
graphs illustrating the average T- and R-type calcium current
densities (pA pF-1) ± SEM values for DRGs treated with vehicle
(control; open white and open blue bars) or 10 μM TAT-CBD3
(yellow) TAT-CBD3A6K (blue) bath-applied for at least 10 min.
Maximal current inhibition for both T- and R-type currents was
observed at ~5 min and plateaued thereafter. The number of cells
are indicated in parentheses. The asterisk denote statistical
significance (p< 0.05; one-way analysis of variance with Dunnett’s
post-hoc test) compared to the untreated control cells.
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required for the parent TAT-CBD3 peptide. Our data sug-
gests that the TAT-CBD3A6K peptide affects neuropathic
pain signaling by blocking T-, R-, and/or N-type calcium
channels on primary sensory neurons. That the T- and R-
type calcium channels are thought to play an important
role in the genesis of repetitive firing and pace-making
activity in neurons [34] suggests that these calcium chan-
nels have a potentially unique function in primary afferent
neuronal excitability (Figure 8) [34-37].
The precise physiological function of DRG neurons
expressing T- and R-type Ca2+ channels is not fully
understood. The involvement of R-type channel in
modulation of hyperexcitability of DRG neurons has yet
to be discerned, but given their function in controlling
burst firing in other neurons in the CNS, they may prove
to have similar function in the PNS. In contrast, T-type
Ca2+ channels in DRG have been shown to be involved
in modulating the excitability of DRG neurons [37,38].
Low voltage-activated calcium channels (T-type) are
Figure 8 Schematic summarizing effects of CBD3A6K peptide on excitability and T- and R-type calcium channels. The figure shows a
tentative model of the effects of CBD3A6K on an action potential recorded from a primary afferent neuron exhibiting T-type LVACC (arrowheads)
and R-type (CaV2.3) HVACC (arrows). (A) The action potential was elicited by the injection of a depolarizing current. CBD3 blocks the T- but not
R-type currents (B) while CBD3A6K has defined blocking effects on both the T- and the R-type currents (C). T-type calcium currents generally
make little contribution to the rising phase of action potentials because their activation kinetics are slower than sodium channels. However,
R-type calcium channels typically begin to be activated near the peak of the action potential and this calcium current is largest during the falling
phase, when channels have been opened and the driving force on calcium increases. Whether the rapid calcium entry via R-type channels
contributes to the activation of large conductance calcium-activated potassium channels is unknown.
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rons [37]. Three subtypes of T-type Ca2+ channels exist
(CaV3.1–3), however in the peripheral nervous system,
CaV3.2 is the predominant subtype in the rat DRG [39].
CaV3.2 has been implicated in normal tactile function
[40] and has been directly linked to hyperalgesia and
allodynia in various pain animal models [22,31,41-43].
Strong evidence suggests that the T-type calcium
channel, particularly CaV3.2, in DRGs is involved in the
initiation and maintenance of chronic neuropathic pain.
For instance, intrathecal treatment with the oligodeoxy-
nucleotide antisense targeting CaV3.2 reduced normal
nociception and neuropathic pain in rats [44]. These rats
had decreased T-current density in corresponding lum-
bar DRG neurons, diminished expression of T-channel
immunoreactivity in DRG tissue, and decreased CaV3.2
mRNA transcript expression in DRGs. Jagodic and col-
leagues have demonstrated similar events in nociceptive
neurons (increased T-current density) following the
chronic constriction injury (CCI) model of neuropathic
pain in rats [45], while systemic injections of mibefradil
and ethosuximide, both blockers of T-type calciumchannels, reversed CCI-induced neuropathic pain [3].
Interestingly, Mibefradil does not cross the blood brain
barrier in significant concentrations, and is thus devoid
of CNS effects [4]. However, the blood nerve barrier sur-
rounding the PNS is composed of fenestrated epineurial-
microvessels that do not possess tight junctions and
would likely allow passage of substances (such as the
peptides tested here) within the blood circulation into
the contact with peripheral nerves and ganglia [46].
Pathirathna and co-workers [47] also reported that
(3β,5α,17β)-17-hydroxyestrane-3-carbonitrile (ECN), a
neuroactive steroid and T-channel blocker, alleviated
neuropathic pain in rats with SNL. Conversely, up-
regulation of CaV3.2/T-type channels has been show to
contribute to the maintenance of neuropathic pain fol-
lowing spinal nerve injury [48]. T-type calcium channels
have also been implicated in diabetic neuropathy models
of neuropathic pain [22,31,49,50] with CaV3.2 knockout
exhibiting attenuated acute pain responses [42]. In this
report we cannot confirm that our peptide is acting spe-
cifically on the CaV3.2, however we report that TAT-
CBD3 and TAT-CBD3A6K are effective in blocking T-
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block AIDS therapy-induced painful peripheral neur-
opathy in vivo. These data reveal that TAT-CBD3A6K
may be attenuating chronic neuropathic pain by decreas-
ing sensory neuron neuronal excitability via blocking T-
type calcium channels in the peripheral nervous system.
Thus, these studies suggest that a major function of T-
type calcium channels in DRG sensory neurons is to
support nociceptive signals.
Though there is precedence for the role neuronal T-
type channels play in the peripheral pain pathway, the
association that R-type channels have with nociceptive
processing in various pain conditions is less well-known
[7,8]. R-type channels have been shown to be present in
rat DRG neurons [10,11], where nociceptive small diam-
eter DRG sensory neurons show higher levels of R-type
channel mRNA than larger DRG neurons [51]. These
primary afferents are thought to contribute to nocicep-
tive processing in various nerve injury paradigms. For
example, R-type channel knockout mice exhibit reduced
responses to inflammatory pain stimuli [7,8], while noci-
ceptive transmission in nerve injured rodents is inhibited
by spinal administration of SNX-482 but not sham-
operated control rats [7,8]. These results are supported
by an earlier study by Murakami and colleagues [52] and
together suggest that the influence that R-type currents
exert in the nociceptive pathway is state-dependent and
does not influence normal physiological pain. That ad-
ministration of TAT-CBD3A6K effectively reduces both
T- and R-type currents, reduces sensory neuron excit-
ability, and attenuates neuropathic pain suggests that
these calcium channels may both be important in pain
transmission and neuropathic pain. Evidence linking
block of T- and R-type calcium channels to analgesia
can be surmised from the work of Dickenson and collea-
gues who reported that the CaV2.3 antagonist SNX-482
reduces primary afferent-mediated dorsal horn neuronal
responses in a rat model of chronic neuropathic pain
(spinal nerve ligation) [8] and Li and colleagues who
reported that intrathecal administration of the T-type
channel blocker mibefradil suppresses thermal hyper-
algesia and allodynia in the chronic compression of dor-
sal root ganglion (CCD) model of neuropathic pain [53].
As was previously reported, our parent peptide TAT-
CBD3 decreased neuropeptide release from sensory neu-
rons, reduced excitatory synaptic transmission in dorsal
horn neurons and transiently reversed neuropathic pain
due to an antiretroviral drug [15] via inhibition of
N-type calcium channel, CaV2.2. Surprisingly, TAT-
CBD3A6K did not alter depolarization-induced release
of CGRP which is contrary to omega-conotoxin inhibi-
tory release of CGRP by sensory neurons (via N-type
channels) [13,54,55]. However, that capsaicin-evoked
release was reduced by ~30% by TAT-CBD3A6K isconsistent with the effects of TAT-CBD3 reported by us
earlier [15]. Thus, we cannot rule out possible effects of
TAT-CBD3A6K on CaV2.2 as Ca2+ currents via this
channel were not tested here. Furthermore, the differen-
tial stimulus-dependent block of CGRP release observed
here may be dependent on (i) nerve growth factor
(NGF)-sensitive sensory neurons as chronic exposure
with NGF significantly and concentration-dependently
serves to increase capsaicin-evoked CGRP release [56]
or (ii) a requirement of a higher concentration for inhib-
ition of CGRP release considering TAT-CBD3A6K seems
to have a greater action on T- and R-type channels than
TAT-CBD3 at the same concentration (Figure 7C). Im-
portantly, our data suggest that TAT-CBD3A6K peptide
has multiple targets of action – within the calcium chan-
nel family – all of which may contribute to anti-
nociception. Although not tested here, it is possible that
TAT-CBD3A6K’s mechanism of action may involve
binding to T- and R-type channels in their first intracel-
lular loops or distal parts of the carboxyl-termini –
regions which we have previously demonstrated to be
the sites of binding of TAT-CBD3 [15]. Sequence align-
ments reveal relatively high homology between the initial
segment of the first intracellular loop of N- compared to
R-, T-type channels but little to no homology in the
remaining 60% of the first intracellular loop or the carb-
oxyl termini of these channels (data not shown). We also
show that the wild type TAT-CBD3 peptide reduces cur-
rents via T- but not R-type calcium channels. Import-
antly, N-type calcium channels are present in DRG
neurons with T-type calcium channels suggesting that
these peptides may interact with several subtypes of cal-
cium channels in the same neurons [57]. That the block
develops over minutes suggests that the peptides are not
direct channel blockers and is consistent with our earlier
findings that TAT-CBD3 works, at least in part, by inter-
fering with anterograde trafficking of CaV2.2 [15]. This
time frame of ~10 min is entirely compatible with an ef-
fect on trafficking; for example, acute activation of phos-
phatidylinositol 3-kinase by insulin-like growth factor 1
in DRG neurons leads to rapid translocation of CaV2.2
to the plasma membrane [58]. Moreover, our observa-
tion that the TAT-CBD3 containing scaffold peptides in-
hibit N, T-, and R-type currents suggests these peptides
may disrupt a generalized mechanism of calcium chan-
nel trafficking.
It is possible that other ion channels that control neur-
onal excitability, such as Na+ or K+, could be modulated
by our peptide. However, we have previously reported
that our parent peptide, TAT-CBD3, does not alter Na+
channels [15] nor does full-length CRMP-2 [13], likely
ruling out Na+ channel inhibition as a cause of the
decreased neuronal excitability observed here. Ca2+ in-
flux via HVACC is also coupled to big conductance
Piekarz et al. Molecular Pain 2012, 8:54 Page 14 of 19
http://www.molecularpain.com/content/8/1/54Ca2+-dependent K+ (BKCa) channels [59] which contrib-
ute to the modulation of both excitability and AP dur-
ation in rat DRG sensory neurons [60,61]. It remains to
be tested if BKCa channels are affected by our peptide
given its effect of reducing calcium via R- and N-type
HVACC.Conclusions
These studies revealed that systemic administration of a
structurally stable TAT-CBD3A6K peptide reverses d4T-
induced nociceptive behavior and reduces currents via
T-and R-type calcium channels implicating an inter-
action with CRMP-2 as being an important contributor
of hyperexcitability of sensory neurons. The discovery of
TAT-CBD3A6K offers a new approach for modulating
individual Ca2+ channels and treatment of neuropathic
pain. The present demonstration of the ability of TAT-
CBD3A6K extends the potential therapeutic utility of T-
and R-type calcium channel blockers in neuropathic pain
states.Methods
Animals
Pathogen-free, adult female Sprague–Dawley rats (150–
200 g; Harlan Laboratories, Madison, WI) were housed
in temperature (23 ± 3°C) and light (12-hlight: 12-h dark
cycle; lights on at 07:00 h) controlled rooms with stand-
ard rodent chow and water available ad libitum. Experi-
ments were performed during the light cycle. These
experiments were approved by the Institutional Animal
Care and Use Committee of Indiana University/Purdue
University in Indianapolis. All procedures were con-
ducted in accordance with the Guide for Care and Use
of Laboratory Animals published by the National Insti-
tutes of Health and the ethical guidelines of the Inter-
national Association for the Study of Pain. All animals
were randomly assigned to either treatment or control
groups.Peptides
TAT-CBD3 (YGRKKRRQRRRARSRLAELRGVPRGL; the
transduction domain of the HIV TAT protein is indicated
in the underlined text), TAT-CBD3A6K (YGRKKRRQRR-
RARSRLKELRGVPRGL; italicized residue denotes a lysine
instead of an alanine at that position) and TAT-CBD3 re-
verse (YGRKKRRQRRRLGRPVGRLEALRSRA; a reversed
version of the CBD3 sequence with no homology to any
known sequence) were synthesized by GenScript USA
Inc. (Piscataway, NJ) and verified by mass spectroscopy
(Department of Chemistry, IUSM) prior to use. Peptides
were dissolved in saline prior to use.Purification/Enrichment of Ca2+channels from
synaptosomes
To prepare a rich source of Ca2+ channels for the far-
Western analyses (see below), synaptosomes from postna-
tal day 1 (PN1) rat brains were solubilized with digitonin
and enriched by chromatography on WGA-Sepharose as
described previously [62-64]. Briefly, 25 PN1 rat brains
were homogenized in 180 ml of 320 mM sucrose with a
glass-Teflon homogenizer. After a short centrifugation
(5000 rpm, 2 min), the supernatant (SN) was centrifuged
(42,000 rpm, 60 min). The membranes were solubilized
with 1.2% digitonin, 80 mM sodium phosphate buffer, pH
7.4 for 20 min. Unsolubilized material was removed by
the centrifugation as before, and the supernatant (S3) was
poured over a 40 ml WGA-Sepharose column (50 ml/h).
After incubation for 1 hr at 4°C, the column was washed
with 10 column volumes of 0.1% digitonin, 75 mMNaCl,
50 mM sodium phosphate, 10 mMTris–HCl (pH 7.4) at a
flow rate of 50 ml/hr. The glycoproteins bound to the
WGA-Sepharose column were eluted with 100 mM N-
acetyl-D-glucosamine (Sigma, St. Louis, MO) in the same
buffer at a flow rate of 50 ml/hr. Three milliliter fractions
were collected and the protein concentration of each frac-
tion was determined by BCA protein assay kit (Thermo
Fisher Scientific, Shelbyville, IN).
To further enrich for Ca2+ channels, WGA-column
fractions were incubated for 4 hr on ice with 200 μl of
heparin-agarose [65]. The resin was washed four times
with 0.2% CHAPS, 10 mMTris–HCl, pH 7.4, and once
with 10 mMTris–HCl, pH 7.4. Ca2+ channels were gen-
tly extracted for 30 min at 50°C with 100 μl of 5% SDS,
20 mMdithiothreitol, 125 mMTris–HCl, pH 6.8, 10%
sucrose, 20 mM EDTA.
Peptide spots arrays and Far Westerns
Peptide arrays harboring amino acid changes at every
single position in the 15 amino acid length of CBD3 were
constructed using the SPOTS-synthesis method [66-69].
Standard 9-fluorenylmethoxy carbonyl (Fmoc) chemistry
wasused to synthesis the peptides on cellulose mem-
branes prederivatized with a polyethylene glycerol spacer
(Intavis AG, Cologne, Germany). Fmoc protected and
activated amino acids (Intavis) were spotted in arrays on
150 mm by 100 mm membranes using the IntavisMulti-
Pep robot. Membranes were probed in a far-Western
manner with an antibody against CaV2.2 (Calbiochem-
Inc, La Jolla, CA)[12]. Briefly, peptides were immobilized
on a nitrocellulose membrane which was then soaked in
CAPS buffer (10 mM CAPS pH 11.0 and 20% methanol)
for 30 min, washed once with TBST, and then blocked
for 1 h at room temperature with gentle shaking in TBST
containing 5% non-fat milk and finally incubated with a
purified synaptosome fraction enriched in Ca2+ channels
for 1 h at room temperature with gentle shaking. Next,
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CaV2.2 for 2 h at room temperature with gentle shaking,
followed by washing with TBST. Finally, the membrane
was incubated in secondary antibody (horseradish
peroxidase-conjugated goat anti-rabbit; 1:10,000) for
45 min, washed for 30 min in TBST and developed using
enhanced chemiluminescence.
Molecular dynamics (MD) simulations of CBD3 wildtype
and mutant peptides
The structure of the wild-type and A6K mutant peptides
were generated using PyMOL (Version 1.5.0.1 Schrödin-
ger, LLC). The coordinates were loaded into Maestro
(version 9.2, Schrödinger, LLC, New York, NY). The
program was used to protonate the peptides and assign
atomic charges. Energy minimization was carried out
using the Impact module of the Schrodinger package.
The resulting structures were immersed into a TIP3P
[70] water molecule such that no atom in the complex
was within 14 Å from any side of the box. The peptides
were neutralized with Na+ or Cl-counterions using the
Leap program from the package [71]. An annealing
process equilibrated the solvated structures before pro-
duction runs were carried out using the pmemd module
in AMBER. MD snapshots were saved every 1 ps, yield-
ing 10,000 structures per trajectory. By assigning differ-
ent initial velocities, 10 independent trajectories of 10 ns
in length were collected for each of the peptides. The
first 2 ns of trajectories were cut off for equilibrium
using ptraj program in AMBER. 1,000 snapshots were
selected from every 8n s trajectory. The root-mean-
square deviation (RMSD) for backbone atoms was deter-
mined using 1,000 snapshots collected from each of the
10 trajectories per peptide.
d4T model of peripheral neuropathy
Hyperalgesia and allodynia were established by a single
injection (50 mg/kg) of the antiretroviral drug 2′,3′-
didehydro-3’-deoxythymidine (d4T, Sigma) given i.p. A
single administration of d4T produced a significant bilat-
eral decrease in paw withdrawal threshold to von Frey
hair stimulation from post-injection day (PID) 3 through
the last day of testing at PID21 [72].
The von Frey test was performed on the area of the
hind paws as previously described [73-76]. Briefly, the
rat was placed on a metal mesh floor and covered with a
transparent plastic dome wherein the animal rested
quietly after an initial few minutes of exploration. Ani-
mals were habituated to this testing apparatus for 15
minutes a day, two days prior to pre-injection behavioral
testing. Following acclimation, each filament was applied
to 6 positions spaced across the glabrous side of the hind
paw; two distinct locations for the distribution of each
nerve branch (saphenous, tibial and sural). Mechanicalstimuli were applied with 7 filaments, each differing in
the bending force delivered (10, 20, 40, 60, 80, 100, and
120 mN), but each fitted a flat tip and a fixed diameter
of 0.2 mm. The force equivalence of mN to grams is:
100 mN=10.2 grams. The filaments were tested in order
of ascending force, with each filament delivered for 1
second in sequence from the 1st to the 6th spot alter-
nately from one paw to the other. The inter-stimulus
interval was 10–15 seconds. A cutoff value of 120 mN
was used; animals that did not respond at 120 mN were
assigned that value.
Measurements were taken on 3 successive days before
rats were subjected to either a TAT-CBD3 (30 mg/kg
and 10 mg/kg) TAT-CBD3A6K (10 mg/kg) and TAT-
CBD3 reverse (10 mg/kg). Stimuli were applied ran-
domly to left and right hind paws to determine the
stimulus intensity threshold stiffness required to elicit a
paw withdrawal response. The incidence of foot with-
drawal was expressed as a percentage of six applications
of each filament as a function of force. A Hill equation
was fitted to the function (Origin version 6.0, Microcal
Software) relating the percentage of indentations elicit-
ing a withdrawal to the force of indentation. From this
equation, the threshold force was obtained and defined
as the force corresponding to a 50% withdrawal rate. A
threshold that exhibits at least a −20 mN difference from
the baseline threshold of testing in a given animal is rep-
resentative of neuropathic pain [76].
Threshold values were statistically analyzed for each
foot separately and the significance of differences be-
tween the average of at least two pre-injection tests and
the mean obtained for each post-injection test. In all
tests, baseline data were obtained for the d4T-treated and
sham-treated groups before drug or vehicle administra-
tion. Within each treatment group, post-administration
means were compared with the baseline values by
repeated measures analyses of variance (RMANOVA)
followed by post hoc pairwise comparisons (Student-
Newman-Keuls Method). A probability level of p <0.05
indicates significance.
Preparation of acutely dissociated dorsal root ganglion
neurons
Lumbar 1–6 (L1-L6) DRGs were acutely dissociated
using methods described previously [77]. Briefly, L1-L6
dorsal root ganglia (DRGs) were removed from naïve
Sprague–Dawley rats. The DRGs were treated with col-
lagenase A and collagenase D in HBSS for 20 minutes
(1 mg/ml; Roche Applied Science, Indianapolis, IN),
followed by treatment with papain (30 units/ml,
Worthington Biochemical, Lakewood, NJ) in HBSS con-
taining 0.5 mM EDTA and cysteine for ~ 20 min at 35°C.
The cells were then dissociated via mechanical disruption
in culture media containing 1 mg/ml bovine serum
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MO). The culture media was DMEM, Ham's F12 mix-
ture, supplemented with 10% fetal bovine serum, penicil-
lin and streptomycin (100 μg/ml and 100 U/ml), N2 (Life
Technologies) and 20 nM NGF (Sigma-Aldrich, St.
Louis, MO). The cells were then plated on coverslips
coated with poly-L lysine and laminin (1 mg/ml) and
incubated for 2–3 hours before the wells were flooded
with additional media. The cells were then allowed to sit
undisturbed for 4–18 hours to adhere at 37°C (with 5%
CO2) prior to electrophysiology.
Current clamp electrophysiology
Electrophysiology experiments were performed using a
modified method described previously [13,77]. Sharp-
electrode intracellular recordings were obtained 4–18 h
after dissociation. Coverslips were transferred to a
recording chamber that was mounted on the stage of an
inverted microscope (Nikon Eclipse Ti, Nikon Instru-
ments Inc., Melville, NY). The chamber was perfused
with a bath solution containing (mM): NaCl 120, KCl 3,
CaCl2 1, MgCl2 1, Hepes 10, Glucose 10, adjusted to pH
7.4 and osmolarity 300 mosM. The recordings were
obtained at room temperature. Intracellular recording
electrodes were fabricated from borosilicate glass (World
Precision Instruments, Sarasota, FL) and pulled on a
Flaming/Brown micropipette puller (P-98, Sutter Instru-
ments, Novato, CA). Electrodes were filled with 1.0 M
KCl (impedance: 40–80 MΩ) and positioned by a micro-
manipulator (Newport Corporation, Irvine, CA). Nega-
tive 0.1 nA current injection was used to bridge-balance
the electrode resistance. Prior to electrode impalement,
the size of the soma to be recorded was classified
according to its diameter as small (≤30 μm), medium
(31–45 μm) and large (≥45 μm). Only small-to-medium
size neurons were used in these experiments as these
neurons are considered to have nociceptive properties
and express T-currents [22,38,78]. Electrophysiological
recordings were performed with continuous current-
clamp in bridge mode using an AxoClamp-2B amplifier,
stored digitally via Digidata 1322A interface, and ana-
lyzed offline with pClamp 9 software (Molecular Devices,
Inc., Downingtown, PA). A neuron was accepted for
study only when it exhibited a resting membrane poten-
tial (RMP) more negative than −45 mV. Action potentials
were evoked by injecting current steps of 1 s duration
through the intracellular recording electrode from
0.1 nA in increments of 0.1 nA until evoking 4–6 action
potentials per current pulse, or reaching 0.4 nA. Baseline
neuronal excitability was measured by injecting 1-s
current pulses into the soma every 30 s. Following 3 con-
trol current injections, peptides were applied to the
coverslip (final concentration of 10 μM) and current
injections continued every 30 s. Neuronal excitability wasmeasured as number of action potentials elicited per
current pulse before and after addition of peptides.
Whole cell voltage-clamp electrophysiology
Recordings were obtained from acutely dissociated DRG
neurons as described previously [13]. To isolate calcium
currents, Na+ and K+ currents were blocked with 1 μMte-
trodotoxin (TTX; Alomone Laboratories), and 30 mMte-
traethylammonium chloride (TEA-Cl; Sigma). To isolate
T-type calcium currents cells were held at −90 mV and
bathed in recording solutions containing 5 μM Nifedipine
(Sigma), 500 nM ω-Conotoxin GVIA (Alomone Labora-
tories), and 200 nM ω-Agatoxin IVA (Alomone Laborator-
ies). Extracellular recording solution (at ~315 mOsm)
consisted of (in mM): 110 N-methyl-D-glucamine
(NMDG), 10 BaCl2, 30 TEA-Cl, 10 HEPES, 10 glucose,
0.001 TTX, 0.005 nifedipine, 0.0005 ω-Conotoxin GVIA,
and 0.0002 ω-Agatoxin IVA. The intracellular recording
solution (at ~305 mOsm) consisted of (in mM): contained
150 CsCl2, 10 HEPES, 5 Mg-ATP, 5 BAPTA, pH at 7.2
with KOH. Fire polished recording pipettes, 2–5 MΩ
resistances were used for all recordings. Whole cell
recordings were obtained with a HEKA EPC-10 USB
(HEKA Instruments Inc.); data were acquired with Patch-
master (HEKA) and analyzed with Fitmaster (HEKA).
Capacitive artifacts were fully compensated and series re-
sistance was compensated by ~70%. Recordings made
from cells with greater than a 5 mV shift in series resist-
ance compensation error were excluded from analysis. All
experiments were performed at room temperature (~23°C).
The currents were filtered at 5 kHz and sampled at
2 kHz using Patchmaster (HEKA).
Whole cell voltage protocols and data analysis
In order to isolate T-type calcium currents cells were
held at −90 mV. After obtaining whole cell configur-
ation, cells were allowed to equilibrate for 2 minutes be-
fore data acquisition began. During data acquisition
several protocols were executed including ramp depolar-
izations from −60 mV to +20 mV for 2 sec and step
depolarizations from −60 mV to +50 mV in 5 mV incre-
ments. Leak currents were subtracted online using a
–P/5 procedure. The activation of Ca2+ channels from
DRGs was well described by the Boltzmann relation: G/
Gmax= 1/{1 + exp[(V-V50%)/kn]}, where G is peak con-
ductance, Gmax is fitted maximal G, V50% is half-
activation voltage, and kn is the slope factor. Data were
acquired using a HEKA EPC-10 amplifier (HEKA) and
analyzed using Fitmaster (HEKA) and Origin 8.0 soft-
ware (Microcal, Northampton, MA).
Stimulated iCGRP release from rat DRGs in culture
Measurement of stimulus-evoked release and content of
immunoreactive CGRP (iCGRP) from isolated sensory
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14 days in culture, the basal or resting release of iCGRP
was measured from aliquots of media removed from
cells incubated for 10 minutes in non-depolarizing
HEPES buffer consisting of (in mM): 25 HEPES, 135
NaCl, 3.5 KCl, 2.5 CaCl2, 1 MgCl2, 3.3 dextrose, and
0.1% (w/v) bovine serum albumin, pH 7.4, and main-
tained at 37°C. The buffer was removed and the cells
were re-exposed to the same HEPES buffer in the pres-
ence of peptide or vehicle control and then incubated in
either a depolarizing HEPES buffer (50 mM KCl) or a
capsaicin-containing HEPES buffer (30 nM Cap) for 10
minutes, following which media was removed and ali-
quotted. The cells were finally incubated again with
non-depolarizing HEPES buffer with 3.5 mM KCl to re-
establish resting release levels, and the buffer was
removed and aliquotted. The amount of iCGRP released
was measured in aliquots of the incubation samples by a
radioimmunoassay (RIA). The minimum amount of
iCGRP detected by the RIA is 5 fmol with a 95% confi-
dence interval68. The remaining peptide content in each
well was determined by exposing the cells to 2 N acetic
acid for 10 minutes. Aliquots of the acid solution were
diluted with HEPES buffer and similarly assay for
iCGRP. This value was added to the amount of iCGRP
released in the previous incubations to yield the total
iCGRP content per well. The release of iCGRP during
the 10 min incubation periods is expressed as percent of
the total content. DRGs were either exposed to TAT-
CBD3A6K peptides (10 μM) throughout the first basal
wash and throughout the high K+ exposures. A mini-
mum of three different preparations were used for each
condition.
Additional file
Additional file 1: Figure S1. Movie illustrating molecular dynamics
simulations of the wild type CBD3 and the mutant CBD3A6K peptides.
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